Polatuzumab vedotin (Pola), an antibody–drug conjugate targeting CD79b, has reshaped frontline therapy for diffuse large B-cell lymphoma (DLBCL) through the landmark POLARIX trial. The gene discussed is POLA1; the disease is diffuse large B-cell lymphoma.